Production (Stage)
Anika Therapeutics, Inc.
ANIK
$11.24
-$0.53-4.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.17M | 30.60M | 38.75M | 41.92M | 29.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.17M | 30.60M | 38.75M | 41.92M | 29.02M |
| Cost of Revenue | 11.49M | 12.87M | 37.31M | 14.56M | 10.05M |
| Gross Profit | 14.68M | 17.73M | 1.44M | 27.37M | 18.98M |
| SG&A Expenses | 12.91M | 11.32M | 19.11M | 19.81M | 15.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.45M | 30.70M | 63.67M | 41.76M | 31.53M |
| Operating Income | -4.28M | -100.00K | -24.92M | 161.00K | -2.51M |
| Income Before Tax | -3.87M | 38.00K | -27.61M | 756.00K | -1.91M |
| Income Tax Expenses | 89.00K | 2.52M | 2.31M | 844.00K | 43.00K |
| Earnings from Continuing Operations | -3.96M | -2.49M | -29.92M | -88.00K | -1.96M |
| Earnings from Discontinued Operations | -915.00K | -19.38M | -- | -- | -2.56M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.87M | -21.87M | -29.92M | -88.00K | -4.51M |
| EBIT | -4.28M | -100.00K | -24.92M | 161.00K | -2.51M |
| EBITDA | -2.69M | 2.09M | -22.73M | 2.22M | -442.00K |
| EPS Basic | -0.34 | -1.50 | -2.03 | -0.01 | -0.31 |
| Normalized Basic EPS | -0.17 | 0.03 | -1.04 | 0.03 | -0.08 |
| EPS Diluted | -0.34 | -1.50 | -2.03 | -0.01 | -0.31 |
| Normalized Diluted EPS | -0.17 | 0.03 | -1.04 | 0.03 | -0.08 |
| Average Basic Shares Outstanding | 14.30M | 14.58M | 14.77M | 14.84M | 14.70M |
| Average Diluted Shares Outstanding | 14.30M | 14.62M | 14.77M | 14.84M | 14.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |